<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35877814</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>807</StartPage><EndPage>818</EndPage><MedlinePgn>807-818</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26462</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Plasma phosphorylated tau (p-tau<sub>181</sub> ) is reliably elevated in Alzheimer's disease (AD), but less explored is its specificity relative to other neurodegenerative conditions. Here, we find novel evidence that plasma p-tau<sub>181</sub> is elevated in amyotrophic lateral sclerosis (ALS), a neurodegenerative condition typically lacking tau pathology. We performed a detailed evaluation to identify the clinical correlates of elevated p-tau<sub>181</sub> in ALS.</AbstractText><AbstractText Label="METHODS">Patients were clinically or pathologically diagnosed with ALS (n&#xa0;=&#xa0;130) or AD (n&#xa0;=&#xa0;79), or were healthy non-impaired controls (n&#xa0;=&#xa0;26). Receiver operating characteristic (ROC) curves were analyzed and area under the curve (AUC) was used to discriminate AD from ALS. Within ALS, Mann-Whitney-Wilcoxon tests compared analytes by presence/absence of upper motor neuron and lower motor neuron (LMN) signs. Spearman correlations tested associations between plasma p-tau<sub>181</sub> and postmortem neuron loss.</AbstractText><AbstractText Label="RESULTS">A Wilcoxon test showed plasma p-tau<sub>181</sub> was higher in ALS than controls (W&#xa0;=&#xa0;2,600, p&#xa0;=&#xa0;0.000015), and ROC analyses showed plasma p-tau<sub>181</sub> poorly discriminated AD and ALS (AUC&#xa0;=&#xa0;0.60). In ALS, elevated plasma p-tau<sub>181</sub> was associated with LMN signs in cervical (W&#xa0;=&#xa0;827, p&#xa0;=&#xa0;0.0072), thoracic (W&#xa0;=&#xa0;469, p&#xa0;=&#xa0;0.00025), and lumbosacral regions (W&#xa0;=&#xa0;851, p&#xa0;=&#xa0;0.0000029). In support of LMN findings, plasma p-tau<sub>181</sub> was associated with neuron loss in the spinal cord (rho&#xa0;=&#xa0;0.46, p&#xa0;=&#xa0;0.017), but not in the motor cortex (p&#xa0;=&#xa0;0.41). Cerebrospinal spinal fluid p-tau<sub>181</sub> and plasma neurofilament light chain were included as reference analytes, and demonstrate specificity of findings.</AbstractText><AbstractText Label="INTERPRETATION">We found strong evidence that plasma p-tau<sub>181</sub> is elevated in ALS and may be a novel marker specific to LMN dysfunction. ANN NEUROL 2022;92:807-818.</AbstractText><CopyrightInformation>&#xa9; 2022 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cousins</LastName><ForeName>Katheryn A Q</ForeName><Initials>KAQ</Initials><Identifier Source="ORCID">0000-0003-1879-2766</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shellikeri</LastName><ForeName>Sanjana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dratch</LastName><ForeName>Laynie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosario</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amado</LastName><ForeName>Defne A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tropea</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-5599-5098</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS114167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115139</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Potential Conflicts of Interest. LD receives consulting fees from Passage Bio and has received honoraria from the Muscular Dystrophy Association and National Society of Genetic Counselors. All other authors have no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>25</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35877814</ArticleId><ArticleId IdType="mid">NIHMS1825841</ArticleId><ArticleId IdType="pmc">PMC9588516</ArticleId><ArticleId IdType="doi">10.1002/ana.26462</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer&#x2019;s disease biomarkers in a multi-ethnic, community study. Alzheimer&#x2019;s and Dementia 2021;(September 2020):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451860</ArticleId><ArticleId IdType="pubmed">33580742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, Karikari TK, Su&#xe1;rez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer&#x2019;s disease pathology at least 8 years prior to postmortem and improves the clinical characterisation of cognitive decline [Internet]. Acta Neuropathologica 2020;140(3):267&#x2013;278.Available from: 10.1007/s00401-020-02195-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. The Lancet Neurology 2021;20(9):739&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8711249</ArticleId><ArticleId IdType="pubmed">34418401</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia [Internet]. Nature Medicine 2020;26(3):379&#x2013;386.Available from: 10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea TF, Waligorska T, Xie SX, et al. Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer&#x2019;s Disease Pathology and Associated with Cognitive and Functional Decline. Pre-print 2022. 10.2139/ssrn.4007185</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4007185</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al.
Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria [Internet]. Amyotrophic lateral sclerosis and frontotemporal degeneration
2017;18(3-4):153&#x2013;174.Available from: https://www.tandfonline.com/doi/full/10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Breljak D. Molecular basis of amyotrophic lateral sclerosis [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry
2011;35(2):370&#x2013;372.Available from: https://www.sciencedirect.com/science/article/pii/S0278584610002800</Citation><ArticleIdList><ArticleId IdType="pubmed">20655970</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA neurology 2014;71(4):442&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A, D&#x2019;Errico E, Introna A, et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. Journal of neurology 2018;265(10):2353&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nature Medicine 2020;26(3):387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousins KAQ, Irwin DJ, Wolk DA, et al. ATN status in amnestic and non-amnestic Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Brain 2020;143(7):2295&#x2013;2311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364757</ArticleId><ArticleId IdType="pubmed">32666090</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017;88(24):2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, O&#x2019;Reilly EJ, Molsberry S, et al. Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology 2021;97(15):e1466&#x2013;e1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575132</ArticleId><ArticleId IdType="pubmed">34380747</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer&#x2019;s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimer&#x2019;s &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring 2019;11:730&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; dementia: the journal of the Alzheimer&#x2019;s Association 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al.
Cerebrospinal fluid biomarker signature in alzheimer&#x2019;s disease neuroimaging initiative subjects [Internet]. Annals of Neurology
2009;65(4):403&#x2013;413.Available from: https://arxiv.org/abs/PMCID:PMC2696350</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. Jama 1993;269(18):2386&#x2013;2391.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479064</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National institute on aging-Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: A practical approach. Acta Neuropathologica 2012;123(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Arai K, Del Tredici K, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta neuropathologica 2014;128(3):423&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta neuropathologica 2011;121(5):597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. Journal of Neurology, Neurosurgery &amp; Psychiatry 2006;77(3):390&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences 1999;169(1-2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle &amp; nerve 2020;61(4):508&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J, van den Berg-Vos RM, Franssen H, et al. Disease course and prognostic factors of progressive muscular atrophy. Archives of neurology 2007;64(4):522&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006;66(5):647&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Devenney EM, Strikwerda-Brown C, et al. Phenotypic variability in ALS-FTD and effect on survival. Neurology 2020;94(19):e2005&#x2013;e2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">32277059</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam C, Scelsa SN, Macgowan DJL. The clinical course of progressive bulbar palsy. Amyotrophic Lateral Sclerosis 2010;11(4):364&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">20132084</ArticleId></ArticleIdList></Reference><Reference><Citation>Funder DC, Ozer DJ. Evaluating Effect Size in Psychological Research: Sense and Nonsense [Internet]. Advances in Methods and Practices in Psychological Science 2019;2(2):156&#x2013;168.Available from: 10.1177/2515245919847202</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2515245919847202</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele C, Hirschfeld G. Cutpointr: Improved estimation and validation of optimal cutpoints in R. Journal of Statistical Software 2021;98(11):1&#x2013;27.</Citation></Reference><Reference><Citation>Ben-Shachar M, L&#xfc;decke D, Makowski D. effectsize: Estimation of Effect Size Indices and Standardized Parameters [Internet]. Journal of Open Source Software
2020;5(56):2815.Available from: https://github.com/easystats/effectsize</Citation></Reference><Reference><Citation>Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. The American Statistician 1981;35(3):124&#x2013;129.</Citation></Reference><Reference><Citation>Strong MJ, Yang W, Strong WL, et al. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology 2006;66(11):1770&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769962</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Donison NS, Volkening K. Alterations in Tau Metabolism in ALS and ALS-FTSD. Frontiers in Neurology 2020;11:1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719764</ArticleId><ArticleId IdType="pubmed">33329356</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg N, Park SB, Vucic S, et al. Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery &amp; Psychiatry 2017;88(6):474&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529975</ArticleId><ArticleId IdType="pubmed">28003344</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;sler KM, Truffert A, Hess CW, Magistris MR. Quantification of upper motor neuron loss in amyotrophic lateral sclerosis. Clinical neurophysiology 2000;111(12):2208&#x2013;2218.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousins KAQ, Phillips JS, Irwin DJ, et al. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer&#x2019;s &amp; Dementia 2021;17(5):822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119305</ArticleId><ArticleId IdType="pubmed">33226735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA neurology 2017;74(5):525&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of clinical and translational neurology 2020;7(7):1103&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I, Lleo A, Karydas A, et al. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology 2021;96(5):e671&#x2013;e683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884995</ArticleId><ArticleId IdType="pubmed">33199433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathology and applied neurobiology 2019;45(3):291&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, et al. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta neuropathologica 2012;124(3):339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Versluys L, Ervilha Pereira P, Schuermans N, et al.
Expanding the TDP-43 Proteinopathy Pathway From Neurons to Muscle: Physiological and Pathophysiological Functions [Internet]. 2022;16Available from: https://www.frontiersin.org/article/10.3389/fnins.2022.815765</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.815765</ArticleId><ArticleId IdType="pmc">PMC8851062</ArticleId><ArticleId IdType="pubmed">35185458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults NV, Seeherman S, Sariipek NE, et al. Tau Protein in Lung Smooth Muscle Cells. Journal of Respiration 2020;1(1):30&#x2013;39.</Citation></Reference><Reference><Citation>Maurage C, Bussiere T, Sergeant N, et al. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathology and applied neurobiology 2004;30(6):624&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541003</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens CH, Guthrie NJ, Roijen M van, et al. Increased tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. Journal of Neuropathology &amp; Experimental Neurology 2019;78(7):605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967836</ArticleId><ArticleId IdType="pubmed">31131395</ArticleId></ArticleIdList></Reference><Reference><Citation>Vintilescu CR, Afreen S, Rubino AE, Ferreira A. The Neurotoxic Tau 45-230 Fragment Accumulates in Upper and Lower Motor Neurons in Amyotrophic Lateral Sclerosis Subjects. Molecular Medicine 2016;22(1):477&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072411</ArticleId><ArticleId IdType="pubmed">27496042</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozziello T, Amaral AC, Dujardin S, et al. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis postmortem motor cortex and cerebrospinal fluid. Brain Pathology 2022;32(2):e13035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877756</ArticleId><ArticleId IdType="pubmed">34779076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature communications 2021;12(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rutkove SB. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Current opinion in neurology 2018;31(5):640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>